Innoviva Inc (INVA) - Total Liabilities
Based on the latest financial reports, Innoviva Inc (INVA) has total liabilities worth $462.32 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Innoviva Inc operating cash flow efficiency to assess how effectively this company generates cash.
Innoviva Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Innoviva Inc's total liabilities have evolved over time, based on quarterly financial data. Check Innoviva Inc (INVA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Innoviva Inc Competitors by Total Liabilities
The table below lists competitors of Innoviva Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Attendo AB (publ)
ST:ATT
|
Sweden | Skr19.60 Billion |
|
Airport City Ltd
TA:ARPT
|
Israel | ILA8.98 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
Taiwan | NT$378.01 Billion |
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
India | Rs53.08 Billion |
|
Rusta AB (publ)
ST:RUSTA
|
Sweden | Skr7.20 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Innoviva Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Innoviva Inc (INVA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innoviva Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innoviva Inc (2000–2025)
The table below shows the annual total liabilities of Innoviva Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $462.32 Million | -24.20% |
| 2024-12-31 | $609.90 Million | +7.27% |
| 2023-12-31 | $568.55 Million | -14.59% |
| 2022-12-31 | $665.71 Million | +66.24% |
| 2021-12-31 | $400.46 Million | +2.23% |
| 2020-12-31 | $391.73 Million | +2.36% |
| 2019-12-31 | $382.71 Million | -1.65% |
| 2018-12-31 | $389.14 Million | -36.21% |
| 2017-12-31 | $610.04 Million | -16.66% |
| 2016-12-31 | $731.99 Million | -4.53% |
| 2015-12-31 | $766.72 Million | +2.91% |
| 2014-12-31 | $745.00 Million | +94.96% |
| 2013-12-31 | $382.13 Million | +78.94% |
| 2012-12-31 | $213.55 Million | -38.25% |
| 2011-12-31 | $345.83 Million | -2.20% |
| 2010-12-31 | $353.62 Million | -4.53% |
| 2009-12-31 | $370.39 Million | -0.19% |
| 2008-12-31 | $371.11 Million | +62.59% |
| 2007-12-31 | $228.25 Million | +14.63% |
| 2006-12-31 | $199.11 Million | +20.49% |
| 2005-12-31 | $165.25 Million | +72.76% |
| 2004-12-31 | $95.66 Million | -77.49% |
| 2003-12-31 | $425.01 Million | +0.09% |
| 2002-12-31 | $424.65 Million | +1773.59% |
| 2000-12-31 | $22.66 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more